Alteogen Inc.
196170
Rangering i aksjer
#1865
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Aksjekurs
$163.88
Sist synkronisert: 2026-10-19
Markedsverdi
$11.41B
Endring (1 dag)
1.72%
Endring (1 år)
-47.38%
Land
KR
Handel Alteogen Inc. (196170)
Kategori
Healthcare
Driftsmargin for Alteogen Inc. (196170)
Driftsmargin per October 2026 TTM: 47.16%
Ifølge Alteogen Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 47.16%. Ved slutten av 2023 hadde selskapet en driftsmargin på -10.09%.
Historikk for driftsmargin for Alteogen Inc. fra 2012 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 47.16% | 90.93% |
| 2024 | 24.70% | -344.80% |
| 2023 | -10.09% | -90.10% |
| 2022 | -101.97% | 160.06% |
| 2021 | -39.21% | 27,907.14% |
| 2020 | -0.14% | -98.18% |
| 2019 | -7.70% | -86.23% |
| 2018 | -55.90% | 9.61% |
| 2017 | -51.00% | -35.50% |
| 2016 | -79.07% | -3,117.94% |
| 2015 | 2.62% | -74.51% |
| 2014 | 10.28% | -62.39% |
| 2013 | 27.33% | -34.80% |
| 2012 | 41.92% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -99.18% |
US
|
|
| -149.01% | -103.16% |
US
|
|
| 25.57% | -99.46% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.39% |
NL
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.